Theriva Biologics (NYSEAMERICAN:TOVX) Trading 3.5% Higher – What’s Next?

Posted by Hayley Millar on Jan 18th, 2025

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Get Free Report) traded up 3.5% during trading on Friday . The stock traded as high as $1.50 and last traded at $1.48. 95,132 shares were traded during mid-day trading, a decline of 76% from the average session volume of 388,412 shares. The stock had previously closed at $1.43.

Analysts Set New Price Targets

Separately, Maxim Group lowered their target price on shares of Theriva Biologics from $25.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th.

Check Out Our Latest Research Report on Theriva Biologics

Theriva Biologics Stock Up 3.5 %

The firm has a market capitalization of $4.11 million, a PE ratio of -0.04 and a beta of 1.23.

Theriva Biologics (NYSEAMERICAN:TOVX – Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($6.81) EPS for the quarter, missing the consensus estimate of ($6.25) by ($0.56).

Institutional Investors Weigh In On Theriva Biologics

An institutional investor recently bought a new position in Theriva Biologics stock. Anson Funds Management LP acquired a new stake in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned approximately 6.13% of Theriva Biologics as of its most recent SEC filing. 6.17% of the stock is owned by institutional investors.

About Theriva Biologics

(Get Free Report)

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.